<DOC>
	<DOCNO>NCT02499874</DOCNO>
	<brief_summary>The purpose study measure drug level blood find whether reduce dose ( 400mg ) anti-HIV medication Efavirenz safe take pregnancy . The study recruit HIV infect woman take Efavirenz part anti-hiv treatment pregnant . Efavirenz show safe pregnancy standard dose everybody take 600mg day , show level enough treat HIV give birth HIV negative baby . Efavirenz dose 400mg daily work HIV dose give HIV positive pregnant woman . People HIV may benefit use dose efavirenz 400mg instead 600mg , low drug dos could fewer side effect tolerate well . Dose reduction would also make drug cheap . This would allow people treated free money important work fight HIV education prevention program . However , know whether 400mg Efavirenz work well 600mg Efavirenz pregnancy investigator conduct study , aim measure amount Efavirenz 400mg HIV pregnant woman 's body take 400mg Efavirenz day .</brief_summary>
	<brief_title>SSAT063- Pharmacokinetics Efavirenz 400 mg Once Daily During Pregnancy HIV-1 Infected Women</brief_title>
	<detailed_description>Protocol Number : SSAT 063 EudraCT Number : 2014-002615-42 Name Investigational Product : Sustiva Name active ingredient : Efavirenz Study title : Pharmacokinetics Efavirenz 400mg daily pregnancy HIV-1 infected woman Name Non Investigational Medicinal Product : Two nucleoside reverse transcriptase inhibitor ( tenofovir/ emtricitabine tenofovir/lamivudine zidovudine/lamivudine ) Phase study : Phase I Objectives : The objective study : - Primary -To investigate pharmacokinetics Efavirenz 400mg pregnancy . - Secondary - To investigate safety tolerability Efavirenz 400mg pregnancy . - To investigate association genetic polymorphism drug disposition gene drug exposure . Study design : Two centre , approximately 18 week ( exclude screen follow ) , open label , single treatment arm , pharmacokinetic study . Indication : HIV pregnancy Methodology : Measurements steady state pharmacokinetic profile efavirenz third trimester pregnancy 6 week postpartum HIV-infected woman tenofovir/emtricitabine tenofovir/lamivudine zidovudine/lamivudine plus Efavirenz 400mg daily . Planned sample size : The primary endpoint comparison efavirenz Ctrough third trimester pregnancy versus postpartum . The efavirenz Ctrough patient compare two phase use geometric mean ratio ( log10 transform data ) . For sequential design , sample size 25 patient would provide least 80 % power detect decrease efavirenz Ctrough 20 % third trimester pregnancy , compare postpartum phase . Up 35 individual may screen achieve 25 woman complete PK phase . Summary eligibility criterion : Pregnant HIV-infected woman : - Undetectable viral load - CD4 count &gt; 100 cells/mm3 - Stable tenofovir/emtricitabine tenofovir/lamivudine zidovudine/lamivudine plus Efavirenz 600mg daily 12 week Number study centre : Two ( London , UK Kampala , Uganda ) Duration treatment : Approximately 18 week : approximately four week prior week 32 pregnancy 6 week postpartum ( exclude screen follow visit ) Dose route administration : All subject administer oral efavirenz 400mg together rest oral antiretroviral combination ( tenofovir 245mg/emtricitabine 200mg tenofovir 245mg/lamivudine 300mg lamivudine 300mg/zidovudine 600mg ) throughout study period . Criteria evaluation : Pharmacokinetic parameter efavirenz evaluate third trimester ( gestational age week 32 +/- 3 week ) 6 week ( +/- 4 week ) postpartum . Safety tolerability medication also assess question , physical examination laboratory parameter . These perform regular interval drug study . At delivery , possible , cord blood sample take time blood sample mother take . Primary Endpoint : Pharmacokinetics efavirenz 400mg pregnancy . Secondary End point : 1 . Safety tolerability efavirenz 400mg pregnancy . 2 . Association genetic polymorphism drug disposition gene drug exposure .</detailed_description>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Efavirenz</mesh_term>
	<mesh_term>Emtricitabine</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<mesh_term>Lamivudine , zidovudine drug combination</mesh_term>
	<criteria>1 . Evidence personally sign date informed consent document indicate participant inform pertinent aspect study . 2 . HIV1infected pregnant female , stable two nucleos/tide analogue ( tenofovir/emtricitabine tenofovir/lamivudine zidovudine/lamivudine ) efavirenz 600mg daily 12 week willing take efavirenz 400 mg daily gestational age 28 week +/ 3 week . 3 . Undetectable viral load ( local assay ) . 4 . CD4 count &gt; 100 cells/mm3 . 5 . Aged 18 45 year , inclusive . 1 . Viral load â‰¥ 50 copies/mL ( detectable local assay ) . 2 . Evidence organ dysfunction clinically significant deviation normal physical examination , vital sign , ECG clinical laboratory determination . 3 . Positive blood screen chronic hepatitis C ( available locally ) hepatitis B . 4 . Current recent ( within 3 month ) gastrointestinal disease . 5 . Clinically relevant alcohol drug use ( positive urine drug screen ) history alcohol drug use consider Investigator sufficient hinder compliance treatment , followup procedure evaluation adverse event . 6 . Exposure investigational drug placebo within 3 month prior first dose study drug . 7 . Use drug , include overthecounter medication herbal preparation , within two week prior first dose study drug , unless approved/prescribed Principal Investigator know interact study drug .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>